Neurocrine Biosciences | NBIX - 운영 비용





운영 비용 변화 날짜
AbbVie USD 10.27B 538M 2026-03
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cytokinetics USD 200.58M 4.46M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Exelixis USD 359.47M 3.28M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Prothena USD 27.23M 14.95M 2025-12
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Repligen USD 174.27M 3.67M 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Xoma USD 22.84M 1.67M 2024-09